Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 4/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.37 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.37 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.37 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29954381 | 0.81 | CA3 (0.52) | ENPP2CA1CA2HSD17B1HSD17B2 | |
| SCHEMBL309397 | 0.81 | CA3 (0.52) | ENPP2CA1CA2HSD17B1HSD17B2 | |
| SCHEMBL128893 | 0.80 | ENPP2 (0.46) | ENPP2CA1CA2KDM4EMGLL | |
| SCHEMBL28490899 | 0.78 | ENPP2 (0.44) | ENPP2CA1CA2KDM4EMGLL | |
| SCHEMBL1277359 | 0.77 | ENPP2 (0.50) | ENPP2CA1CA2KDM4ETTR | |
| SCHEMBL24303706 | 0.77 | SHBG (0.35) | ENPP2CA1CA2HSD17B1HSD17B2 | |
| SCHEMBL15646351 | 0.76 | CA2 (0.42) | ENPP2CA1CA2MGLLTTR | |
| SCHEMBL177645 | 0.74 | CA2 (0.46) | ENPP2CA1CA2MGLLTTR | |
| SCHEMBL310780 | 0.74 | TTR (0.50) | ENPP2CA1CA2MGLLTTR | |
| SCHEMBL1128990 | 0.74 | CA1 (0.46) | ENPP2CA1CA2MGLLTTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 436 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118240200-A | Low-dielectric fluorine-containing polyarylether resin and preparation method and application thereof | 中国科学院宁波材料技术与工程研究所 | 2024-06-25 | — | — | CN | claimed |
| CN-116731315-B | Boron-containing phthalonitrile resin and preparation method and application thereof | 中国科学院化学研究所 | 2024-06-21 | — | — | CN | claimed |
| CN-118184818-A | Functionalized high molecular polymer, visualized embolism microsphere prepared by microfluidic technology and application | 四川大学 | 2024-06-14 | — | — | CN | claimed |
| CN-118001218-A | Blood sugar response type drug release visual long-acting microneedle and preparation method thereof | 沈阳药科大学 | 2024-05-10 | — | — | CN | claimed |
| CN-116731315-A | Boron-containing phthalonitrile resin and preparation method and application thereof | 中国科学院化学研究所 | 2023-09-12 | — | — | CN | claimed |
| CN-114585396-A | Injectable hydrogel with anti-inflammatory and repair promoting functions, preparation method thereof and application thereof in heart repair | 四川大学 | 2022-06-03 | — | — | CN | claimed |
| US-20260042780-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4663630-A1 | NOVEL BENZIMIDAZOLONE DERIVATIVE COMPOUND AS AUTOTAXIN INHIBITOR | LG Chem, Ltd. (KR) | 2025-12-17 | — | — | EP | disclosed |
| US-20250340563-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | TAKEDA DEVELOPMENT CENTER AMERICAS, INC. | 2025-11-06 | — | — | US | disclosed |
| EP-4116302-B1 | COMPOUND AND PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN PREPARATION OF THERAPEUTIC ANTI-CANCER DRUG | TIANJIN JIKUN MEDICAL TECH CO LTD (CN) | 2025-10-29 | — | — | EP | disclosed |
| US-20250241905-A1 | 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION | 2025-07-31 | — | — | US | disclosed |
| US-20250223291-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION | 2025-07-10 | — | — | US | disclosed |
| US-20250163068-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2025-05-22 | — | — | US | disclosed |
| US-5622961-A | PROSTATE CANCER, SKIN DISORDERS, BALDNESS | ELI LILLY AND COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| US-5622962-A | PROSTATE CANCER, SKIN DISORDERS, BALDNESS | ELI LILLY AND COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| US-5578724-A | INHIBITORS OF 5-ALPHA-REDUCTASE | ELI LILLY AND COMPANY (US) | 1996-11-26 | — | — | US | disclosed |
| WO-1996035422-A1 | METHODS FOR INHIBITING BONE LOSS | ELI LILLY AND COMPANY (US) | 1996-11-14 | — | — | WO | disclosed |
| EP-0742010-A2 | Benzoquinolin-3-ones to inhibit bone loss | ELI LILLY AND COMPANY (US) | 1996-11-13 | — | — | EP | disclosed |
| EP-0733365-A2 | Use of benzoquinolin-3-ones for the treatment and prevention of prostatic cancer | ELI LILLY AND COMPANY (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5550134-A | ADMINISTERING TO A MAMMAL FROM A SERIES OF BENZOQUINOLIN-3-ONE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1996-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250241905-A1 | 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF | HSD3B1, HSD3B2, HSD17B11 | ENPP2 3089/4885CA1 1946/4885CA2 3616/4885 |
| US-20250223291-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | ERBB2, MERTK, ABL1 | ENPP2 3459/4885CA1 4092/4885CA2 1009/4885 |
| US-20250163068-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | ENPP2 384/4885CA1 285/4885CA2 213/4885 |
| US-20250340563-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | NLRP3, NLRP1, NOD1 | ENPP2 2293/4885CA1 4754/4885CA2 4496/4885 |
| US-20260042780-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PTEN, PIK3C2A, PIK3CA | ENPP2 529/4885CA1 1604/4885CA2 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.